ProQuad (measles, mumps, rubella and varicella vaccine (live))

Region: 🇪🇺 EU
Active substance: measles, mumps, rubella and varicella vaccine (live)
Company: Merck Sharp & Dohme B.V.
Status: Authorised
Therapeutic area: Chickenpox; Rubella; Measles; Mumps; Immunization
EU approval: Wed 05 Apr 2006
Application: EMEA/H/C/000622
ATC: J07BD54
Official record: www.ema.europa.eu

Indication

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

🇪🇺 M-M-RVaxPro Authorised · Merck Sharp & Dohme B.V.

Follow ProQuad

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.